Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan H Schatz

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Current Oncology Reports|July 15, 2011
Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategiesJonathan H Schatz
Cell Cycle (Georgetown, Tex.)|November 9, 2011
Targeted cancer therapy: what if the driver is just a messenger?Jonathan H Schatz, Hans-Guido Wendel
Blood Cancer Journal|February 8, 2024
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomasAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Trends in Biotechnology|April 9, 2021
Potency Meets Precision in Nano-optimized ChemotherapeuticsArtavazd Arumov, Asaad Trabolsi, Jonathan H Schatz
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2019
T Cell-Activating Bispecific Antibodies in Cancer TherapyAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Oncotarget|November 27, 2018
eIF4A inhibition: ready for primetime?Tyler A Cunningham, Eli Chapman, Jonathan H Schatz
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 2, 2025
Bispecific Antibodies in Hematologic Malignancies: Attacking the FrontlineToral Shastri, Asaad Trabolsi, Artavazd Arumov, et al.
Aging|November 4, 2015
Kinase overexpressing cancers responsive to drug withdrawalAmit Dipak Amin, Soumya S Rajan, Jonathan H Schatz
Leukemia & Lymphoma|November 7, 2023
Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphomaAustin D Newsam, Caroline A Coughlin, Asaad Trabolsi, et al.
Trends in Biochemical Sciences|December 14, 2020
Jekyll and Hyde: Activating the Hypoxic Translational MachineryJ J David Ho, Jonathan H Schatz, Jim Uniacke, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Current Oncology Reports|July 15, 2011
Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategiesJonathan H Schatz
Cell Cycle (Georgetown, Tex.)|November 9, 2011
Targeted cancer therapy: what if the driver is just a messenger?Jonathan H Schatz, Hans-Guido Wendel
Blood Cancer Journal|February 8, 2024
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomasAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Trends in Biotechnology|April 9, 2021
Potency Meets Precision in Nano-optimized ChemotherapeuticsArtavazd Arumov, Asaad Trabolsi, Jonathan H Schatz
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2019
T Cell-Activating Bispecific Antibodies in Cancer TherapyAsaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
Oncotarget|November 27, 2018
eIF4A inhibition: ready for primetime?Tyler A Cunningham, Eli Chapman, Jonathan H Schatz
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 2, 2025
Bispecific Antibodies in Hematologic Malignancies: Attacking the FrontlineToral Shastri, Asaad Trabolsi, Artavazd Arumov, et al.
Aging|November 4, 2015
Kinase overexpressing cancers responsive to drug withdrawalAmit Dipak Amin, Soumya S Rajan, Jonathan H Schatz
Leukemia & Lymphoma|November 7, 2023
Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphomaAustin D Newsam, Caroline A Coughlin, Asaad Trabolsi, et al.
Trends in Biochemical Sciences|December 14, 2020
Jekyll and Hyde: Activating the Hypoxic Translational MachineryJ J David Ho, Jonathan H Schatz, Jim Uniacke, et al.
Pageof 6